Q-omics provides the consensus-scored RNY4P34 profile across patient tissues and cancer cell-line models. RNY4P34 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNY4P34 is differentially expressed in 6, with the highest sampling consensus in UCEC. Additionally, RNY4P34 RNA expression shows 5,945 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, UCEC, and PDAC as cancer lineages where RNY4P34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNY4P34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNY4P34 survival associations across molecular data types. RNY4P34 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNY4P34 RNA expression–survival associations across cancer types. High RNY4P34 expression shows unfavorable associations in KIRC, ACC, LUAD and READ, but favorable associations in BLCA and STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNY4P34 RNA expression.
This table summarizes RNY4P34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RNY4P34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNY4P34 shows lower tumor expression in KICH and THCA and higher tumor expression in UCEC, ESCA, STAD and BLCA. The UCEC box plot shows higher RNY4P34 RNA expression in tumor versus normal tissue (log2 FC = +0.360, t-test p = .039).
This table shows molecular features associated with RNY4P34 in patient tissues and cancer cell lines. In patient samples, RNY4P34 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
